Assessing Efficacy and Safety of Olopatadine 0.1% Ophthalmic Solution and Bepotastine 1.5% Ophthalmic Solution in Patients with Vernal Keratoconjunctivitis

Description

Abstract (English)

Aim: The purpose of the present study was intended to compare the effectiveness and safety of olopatadine 0.1%
ophthalmic drops and bepotastine besilate 1.5% ophthalmic drops with BD administration to relieve the symptoms
of VKC in a tertiary care hospital in Bihar region.
Methods: The study was done in the Department of Pharmacology, DMCH, Laheriasarai, Darbhanga, Bihar,
India for duration of 10 months. By simple randomization (odd/even number) method, registered patients were
grouped into A and B. Group A and Group B were given olopatadine 0.1% ophthalmic drops and bepotastine
besilate 1.5% ophthalmic drops, respectively, administered one drop in the affected eye twice daily for 6 weeks.
Results: The itching scores among the treatment groups with all follow-ups compared with baseline are not
statistically significant. The mean ocular discomfort scores during each visit. At the 1st, 2nd, and 3rd follow-up,
there is statistical significance in ocular discomfort scores with Group B. In Group B, during the 2nd, 3rd, and 4th
follow-ups, there is statistical significance in watering scores (P < 0.05).
Conclusion: In this study, based on the evaluation of therapeutic performance, bepotastine eye drops proved
quicker relief of symptoms and signs compared to olopatadine eye drops but was not statistically significant which
would prove beneficial for the patients.